<DOC>
	<DOCNO>NCT02020889</DOCNO>
	<brief_summary>The purpose randomize , double-blind study investigate efficacy safety mepolizumab ( 300 milligram [ mg ] administer subcutaneously [ SC ] every 4 week ) compare placebo 52-week study treatment period subject relapse refractory Eosinophilic Granulomatosis Polyangiitis ( EGPA ) receive standard care therapy include background corticosteroid therapy without immunosuppressive therapy . During treatment period , accordance standard care , corticosteroid dose taper . The key outcome study focus evaluation clinical remission , define Birmingham Vasculitis Activity Score ( BVAS ) =0 corticosteroid dose &lt; =4 mg/day prednisolone/prednisone , reduction disease relapse reduction corticosteroid requirement .</brief_summary>
	<brief_title>A Study Investigate Mepolizumab Treatment Eosinophilic Granulomatosis With Polyangiitis</brief_title>
	<detailed_description />
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<criteria>Informed Consent : Able give write informed consent prior participation study , include ability comply requirement restriction list consent form . Subjects must able read , comprehend , write level sufficient complete study related material . Age gender : Male female subject age 18 year old . EGPA diagnosis : subject diagnose EGPA least 6 month base history presence : asthma plus eosinophilia ( &gt; 1.0x10^9/Liter and/or &gt; 10 % leucocyte ) plus least two follow additional feature EGPA ; biopsy show histopathological evidence eosinophilic vasculitis , perivascular eosinophilic infiltration , eosinophilrich granulomatous inflammation ; neuropathy , mono poly ( motor deficit nerve conduction abnormality ) ; pulmonary infiltrates , nonfixed ; sinonasal abnormality ; cardiomyopathy ( establish echocardiography Magnetic Resonance Imaging ) ; glomerulonephritis ( haematuria , red cell cast , proteinuria ) ; alveolar haemorrhage ( bronchoalveolar lavage ) ; palpable purpura ; anti neutrophil cytoplasmic antibody ( ANCA ) positive ( Myeloperoxidase proteinease 3 ) . History relapsing OR refractory disease define : Relapsing disease : Subject must past history least one confirm EGPA relapse ( i.e. , require increase oral corticosteroid ( OCS ) dose , initiation/increased dose immunosuppressive therapy hospitalisation ) within past 2 year occur least 12 week prior Screening ( Visit 1 ) whilst receive dose prednisolone ( equivalent ) &gt; =7.5 milligram per day ( mg/day ) . Refractory disease : Either : Failure attain remission ( BVAS=0 OCS dose &lt; =7.5 mg/day prednisolone equivalent ) within last 6 month follow induction treatment standard regimen , administer least 3 month . Note : ) Subjects receive cyclophosphamide ( CYC ) induction regimen may include minimum 2 week last dose daily oral CYC , 3 week last dose pulse intravenous CYC prior Baseline ( Visit 2 ) , total white blood cell ( WBC ) &gt; =4x10^9/Liter ( tested local laboratory , necessary ) prior randomisation . b ) Subjects received methotrexate , azathioprine , mycophenolate mofetil induction regimen may include stable dose least 4 week prior Baseline ( Visit 2 ) . c ) Subjects receive induction regimen comprise corticosteroid alone may include fail attain remission 3 month treatment AND corticosteroid dose &gt; =15 mg/day prednisolone equivalent 4 week prior Baseline ( Visit 2 ) . Or : Within 6 month prior Screening ( Visit 1 ) , recurrence symptom EGPA ( necessarily meet protocol definition relapse ) whilst taper OCS , occur dose level &gt; =7.5 mg/day prednisolone equivalent . Corticosteroid therapy : Subject must stable dose oral prednisolone prednisone &gt; =7.5 mg/day ( &gt; 50 mg/day ) least 4 week prior Baseline ( Visit 2 ) . Immunosuppressive therapy : If receive immunosuppressive therapy ( exclude cyclophosphamide ) dosage must stable 4 week prior Baseline ( Visit 2 ) study ( dose reduction safety reason permit ) . ECG measurement : QTc ( F ) &lt; 450 msec QTc ( F ) &lt; 480 msec patient bundle branch block . The QTc QT interval correct heart rate accord either Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , another method , machine manual overread . For subject eligibility withdrawal decision , QTcFwill use . For purpose data analysis , QTcF use primary though data use correction formula collect analysed . The QTc base single average QTc value triplicate electrocardiogram ( ECGs ) obtain brief recording period . Female subject : To eligible entry study , female childbearing potential ( FCBP ) must commit consistent correct use acceptable method birth control ( discuss protocol ) begin consent , duration trial 4 month last study drug administration . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Liver Function Tests : obtain Screening ( Visit 1 ) : ALT &lt; 2x ULN ( upper limit normal ) subject background methotrexate azathioprine &lt; 3x ULN ; AST &lt; 2x ULN subject background methotrexate azathioprine &lt; 3x ULN ; Alkaline Phosphatase ≤2.0x ULN ; Bilirubin ≤ 1.5x ULN ( isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) GPA MPA : Diagnosed granulomatosis polyangiitis ( GPA ; previously know Wegener 's granulomatosis ) microscopic polyangiitis ( MPA ) . Organthreatening EGPA : Organthreatening EGPA per European league rheumatism ( EULAR ) criterion , i.e. , organ failure due active vasculitis , creatinine &gt; 5.8 gram per deciliter ( g/dL ) ( &gt; 513 micromole per liter [ µmol/L ] ) within 3 month prior Screening ( Visit 1 ) . Lifethreatening EGPA : Imminently lifethreatening EGPA disease define follow within 3 month prior Screening ( Visit 1 ) ; Intensive care require ; Severe alveolar haemorrhage haemoptysis require transfusion ventilation haemoglobin &lt; 8 gram per liter ( g/dL ) ( &lt; 80 g/L ) drop haemoglobin &gt; 2 g/dL ( &gt; 20 g/L ) 48 hour period due alveolar haemorrhage ; Rapidly progressive glomerulonephritis ( RPGN ) creatinine &gt; 2.5 milligram per deciliter ( mg/dL ) ( &gt; 221 µmol/L ) rise creatinine &gt; 2 mg/dL ( &gt; 177 µmol/L ) 48 hour period ; Severe gastrointestinal ( GI ) involvement , e.g. , gangrene , bleed require surgery ; Severe central nervous system ( CNS ) involvement ; Severe cardiac involvement , e.g. , lifethreatening arrhythmia , cardiac failure : ejection fraction &lt; 20 % , New York Heart Association Class III/IV ( discuss protocol ) , acute myocardial infarction . Malignancy : A current malignancy previous history cancer remission le 12 month prior screen ( Subjects localize carcinoma ( i.e. , basal squamous cell ) skin resect cure exclude ) . Liver disease : Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , esophageal gastric varix persistent jaundice ) , cirrhosis , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Cardiovascular : Subjects severe clinically significant cardiovascular disease uncontrolled standard treatment include limited : Known ejection fraction &lt; 30 % , OR Severe heart failure meet New York Heart Association Class IV ( discuss protocol ) , OR Hospitalised 12 month prior Visit 1 severe heart failure meet New York Heart Association Class III ( discuss protocol ) , OR Angina diagnose less 3 month prior Visit 1 ( Screening ) . Other concurrent medical condition : Subjects know , preexist , clinically significant endocrine , autoimmune , metabolic , neurological , renal , gastrointestinal , hepatic , haematological , respiratory system abnormality associate EGPA uncontrolled standard treatment . Infectious disease : Chronic ongoing active infectious disease require systemic treatment . Parasitic infection : Subjects parasitic infestation within 6 month prior Screening ( Visit 1 ) . Hepatitis status : Diagnosis chronic hepatitis B , evidence positive Hepatitis B surface antigen ( HBsAg ) Screening ( Visit 1 ) . Japan : Subjects positive HBsAg , antibodies HBsAg , i.e. , HBsAb , Hepatitis B core antigen , i.e. , HBcAb , Screening ( Visit 1 ) . Note : Subjects antibodies HBsAg , i.e. , HBsAb positive , ( i.e. , negative HBsAg HBcAb ) history hepatitis B vaccination include . HIV : Subjects know human immunodeficiency virus infection . Hypersensitivity : Subjects know allergy intolerance monoclonal antibody biologic therapy . Previous mepolizumab : Subjects previously receive mepolizumab within 1 year period prior Screening ( Visit 1 ) . Prohibited medication : Subjects receive following : OCS : Subject require oral corticosteroid dose &gt; 50 mg/day prednisolone/prednisone 4week period prior Baseline ( Visit 2 ) ; Intravenous SC corticosteroid 4week period prior Baseline ( Visit 2 ) ; Omalizumab within 130 day prior Screening ( Visit 1 ) ; Cyclophosphamide : oral CYC within 2 week prior Baseline ( Visit 2 ) IV CYC within 3 week prior Baseline ( Visit 2 ) , total WBC &gt; =4x10^9/Liter ( measure use local laboratory necessary ) ; Rituximab within 12 month prior Screening ( Visit 1 ) ; addition , subject must show recovery peripheral Bcell count within normal range ; IV SC immunoglobulin within 6 month prior Screening ( Visit 1 ) ; Interferonα within 6 month prior Screening ( Visit 1 ) ; AntiTNF therapy within 12 week prior Screening ( Visit 1 ) ; AntiCD52 ( alemtuzumab ) within 6 month prior Screening ( Visit 1 ) . Other laboratory parameter exclusion : Creatinine &gt; 2.5 mg/dL ( 221 µmol/L ) ; WBC &lt; 4 x10^9/Liter , Platelet count &lt; 120,000/millimetre cube ( mm^3 ) , Haemoglobin &lt; 8 g/dL ( &lt; 80 g/L ) Pregnancy : Subjects pregnant breastfeeding . Subjects enrol plan become pregnant time study participation . Alcohol/substance abuse : A history ( suspected history ) alcohol misuse substance abuse within 2 year prior Screening ( Visit 1 ) . Other investigational product : Subjects receive treatment investigational drug within past 30 day 5 terminal phase halflives drug whichever longer , prior Screening ( Visit 1 ) ( also include investigational formulation market product ) . Other clinical study : Subject currently participate interventional clinical study . Adherence : Subjects know evidence lack adherence controller medication and/or ability follow physician 's recommendation . French subject : French subject participate study use investigational drug previous 30 day 5 halflives ( whichever longer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>eosinophil</keyword>
	<keyword>SB 240563</keyword>
	<keyword>Churg-Strauss Syndrome</keyword>
	<keyword>quality life</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>safety</keyword>
	<keyword>biomarkers</keyword>
	<keyword>efficacy</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>Eosinophilic granulomatosis polyangiitis</keyword>
</DOC>